Edwards Lifesciences Corporation Company Profile (NYSE:EW)

About Edwards Lifesciences Corporation (NYSE:EW)

Edwards Lifesciences Corporation logoEdwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World. Its products are categorized into three areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care. It also develops hemodynamic monitoring systems that are used to measure a patient's cardiovascular function in the hospital setting. It is developing products, such as the Edwards SAPIEN 3 Ultra System and Edwards SAPIEN XT transcatheter heart valve, among others. Its Transcatheter Heart Valve Therapy and Surgical Heart Valve Therapy products are manufactured in the United States, Singapore and Switzerland. Critical Care products are manufactured in its facilities located in Puerto Rico and the Dominican Republic.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Advanced Medical Equipment & Technology
  • Sub-Industry: Health Care Equipment
  • Symbol: NYSE:EW
  • CUSIP: 28176E10
  • Web: www.edwards.com
Capitalization:
  • Market Cap: $23.66 billion
  • Outstanding Shares: 211,158,000
Average Prices:
  • 50 Day Moving Avg: $111.17
  • 200 Day Moving Avg: $111.78
  • 52 Week Range: $81.12 - $121.45
P/E:
  • Trailing P/E Ratio: 33.98
  • Foreward P/E Ratio: 26.80
  • P/E Growth: 1.81
Sales & Book Value:
  • Annual Revenue: $3.23 billion
  • Price / Sales: 7.32
  • Book Value: $13.93 per share
  • Price / Book: 8.04
Profitability:
  • EBITDA: $1.05 billion
  • Net Margins: 22.16%
  • Return on Equity: 27.17%
  • Return on Assets: 15.91%
Debt:
  • Debt-to-Equity Ratio: 0.35%
  • Current Ratio: 4.06%
  • Quick Ratio: 3.19%
Misc:
  • Average Volume: 1.28 million shs.
  • Beta: 0.62
  • Short Ratio: 1.54
 

Frequently Asked Questions for Edwards Lifesciences Corporation (NYSE:EW)

What is Edwards Lifesciences Corporation's stock symbol?

Edwards Lifesciences Corporation trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

When did Edwards Lifesciences Corporation's stock split? How did Edwards Lifesciences Corporation's stock split work?

Edwards Lifesciences Corporation's stock split on Monday, December 14th 2015. The 2-1 split was announced on Thursday, November 19th 2015. The newly minted shares were payable to shareholders after the closing bell on Friday, December 11th 2015. An investor that had 100 shares of Edwards Lifesciences Corporation stock prior to the split would have 200 shares after the split.

How were Edwards Lifesciences Corporation's earnings last quarter?

Edwards Lifesciences Corporation (NYSE:EW) issued its quarterly earnings data on Wednesday, July, 26th. The company reported $1.08 EPS for the quarter, beating the Zacks' consensus estimate of $0.88 by $0.20. The company earned $842 million during the quarter, compared to analysts' expectations of $839.16 million. Edwards Lifesciences Corporation had a net margin of 22.16% and a return on equity of 27.17%. Edwards Lifesciences Corporation's revenue was up 10.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.76 EPS. View Edwards Lifesciences Corporation's Earnings History.

When will Edwards Lifesciences Corporation make its next earnings announcement?

Edwards Lifesciences Corporation is scheduled to release their next quarterly earnings announcement on Tuesday, October, 24th 2017. View Earnings Estimates for Edwards Lifesciences Corporation.

What guidance has Edwards Lifesciences Corporation issued on next quarter's earnings?

Edwards Lifesciences Corporation updated its FY17 earnings guidance on Wednesday, July, 26th. The company provided earnings per share (EPS) guidance of $3.65-3.85 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.54. The company issued revenue guidance of $, compared to the consensus revenue estimate of $3.35 billion.Edwards Lifesciences Corporation also updated its Q3 guidance to $0.80-0.90 EPS.

Where is Edwards Lifesciences Corporation's stock going? Where will Edwards Lifesciences Corporation's stock price be in 2017?

20 analysts have issued 12 month target prices for Edwards Lifesciences Corporation's stock. Their forecasts range from $14.00 to $155.00. On average, they expect Edwards Lifesciences Corporation's stock price to reach $120.05 in the next twelve months. View Analyst Ratings for Edwards Lifesciences Corporation.

What are analysts saying about Edwards Lifesciences Corporation stock?

Here are some recent quotes from research analysts about Edwards Lifesciences Corporation stock:

  • 1. According to Zacks Investment Research, "Over the last six months, Edwards Lifesciences has outperformed the broader industry. Edwards Lifesciences’ second-quarter 2017 performance was quite promising . Moreover, the raised guidance for 2017 hints at brighter prospects. In fact, the guidance raise was backed by a strong performance by all of the company’s three product lines.   We believe that the recent FDA approvals for several products including SAPIEN 3 THV for valve-in-valve procedures and INSPIRIS RESILIA aortic valve have been boosting investors’ confidence on the stock. However, higher operating expenses raise concerns. The stock’s valuation is also stretched on huge investments in the launch and promotion of products. Stiff competition, currency headwind and reimbursement issues are other challenges." (9/26/2017)
  • 2. Cowen and Company analysts commented, "After hosting meetings with management last week, attending ACC, and reviewing early 1Q'17 MedMine hospital purchasing data, we remain bullish on Edwards' long term growth prospects. We are optimistic that additional layers of growth will be provided by low risk, asymptomatic and moderate AS indications along with EW's mitral and tricuspid platforms. Reiterate Outperform." (3/28/2017)
  • 3. Evercore ISI analysts commented, "With lowered investor expectations, we believe EW shares are poised for a 'catch-up' trade and offers asymmetric risk-reward at current levels. As a result, we are upgrading shares to a Buy, and raising our PT to $110, which offers ~15% upside from current levels." (3/27/2017)

Are investors shorting Edwards Lifesciences Corporation?

Edwards Lifesciences Corporation saw a increase in short interest in the month of September. As of September 15th, there was short interest totalling 3,127,319 shares, an increase of 49.6% from the August 31st total of 2,090,850 shares. Based on an average daily trading volume, of 1,430,982 shares, the days-to-cover ratio is currently 2.2 days. Approximately 1.5% of the company's shares are short sold.

Who are some of Edwards Lifesciences Corporation's key competitors?

Who are Edwards Lifesciences Corporation's key executives?

Edwards Lifesciences Corporation's management team includes the folowing people:

  • Michael A. Mussallem, Chairman of the Board, Chief Executive Officer
  • Scott B. Ullem, Chief Financial Officer, Corporate Vice President
  • Donald E. Bobo Jr., Corporate Vice President - Heart Valve Therapy
  • Catherine M. Szyman, Corporate Vice President- Critical Care
  • Patrick Bruno Verguet, Corporate Vice President- Europe, Middle East and Africa
  • Huimin Wang M.D., Corporate Vice President- Japan, Asia and Pacific
  • Larry L. Wood, Corporate Vice President - Transcatheter Heart Valve Therapy
  • Bernard J. Zovighian, Corporate Vice President -Surgical Heart Valve Therapy
  • Kieran T. Gallahue, Independent Director
  • Leslie Stone Heisz, Independent Director

Who owns Edwards Lifesciences Corporation stock?

Edwards Lifesciences Corporation's stock is owned by many different of retail and institutional investors. Top institutional investors include Fulton Bank N.A. (0.01%) and Bath Savings Trust Co (0.01%). Company insiders that own Edwards Lifesciences Corporation stock include Barbara J Mcneil, Bernard J Zovighian, Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Dylan Sidoo, Huimin Wang, John T Cardis, Kieran Gallahue, Larry L Wood, Michael A Mussallem, Nick Demare, Patrick B Verguet, Robert WA Sellers, Schack Wesley W Von and Steven R Loranger. View Institutional Ownership Trends for Edwards Lifesciences Corporation.

Who sold Edwards Lifesciences Corporation stock? Who is selling Edwards Lifesciences Corporation stock?

Edwards Lifesciences Corporation's stock was sold by a variety of institutional investors in the last quarter, including Fulton Bank N.A.. Company insiders that have sold Edwards Lifesciences Corporation stock in the last year include Bernard J Zovighian, Catherine M Szyman, Donald E Bobo, Jr, Huimin Wang, Larry L Wood, Michael A Mussallem and Patrick B Verguet. View Insider Buying and Selling for Edwards Lifesciences Corporation.

Who bought Edwards Lifesciences Corporation stock? Who is buying Edwards Lifesciences Corporation stock?

Edwards Lifesciences Corporation's stock was purchased by a variety of institutional investors in the last quarter, including Bath Savings Trust Co. Company insiders that have bought Edwards Lifesciences Corporation stock in the last two years include Catherine M Szyman, Dylan Sidoo, Kieran Gallahue, Nick Demare and Steven R Loranger. View Insider Buying and Selling for Edwards Lifesciences Corporation.

How do I buy Edwards Lifesciences Corporation stock?

Shares of Edwards Lifesciences Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Edwards Lifesciences Corporation's stock price today?

One share of Edwards Lifesciences Corporation stock can currently be purchased for approximately $112.03.


MarketBeat Community Rating for Edwards Lifesciences Corporation (NYSE EW)
Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  797 (Vote Outperform)
Underperform Votes:  560 (Vote Underperform)
Total Votes:  1,357
MarketBeat's community ratings are surveys of what our community members think about Edwards Lifesciences Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Edwards Lifesciences Corporation (NYSE:EW) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Hold Ratings, 14 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $120.05 (7.16% upside)
Consensus Price Target History for Edwards Lifesciences Corporation (NYSE:EW)
Price Target History for Edwards Lifesciences Corporation (NYSE:EW)
Analysts' Ratings History for Edwards Lifesciences Corporation (NYSE:EW)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/12/2017Cowen and CompanyReiterated RatingBuy$135.00N/AView Rating Details
10/8/2017Canaccord GenuityReiterated RatingBuy$155.00N/AView Rating Details
9/30/2017Barclays PLCReiterated RatingEqual Weight$120.00LowView Rating Details
9/1/2017Royal Bank Of CanadaReiterated RatingBuy$130.00N/AView Rating Details
9/1/2017BMO Capital MarketsReiterated RatingBuy$132.00N/AView Rating Details
8/28/2017William BlairReiterated RatingOutperform -> OutperformLowView Rating Details
7/27/2017Stifel NicolausReiterated RatingBuy -> Buy$118.00 -> $130.00HighView Rating Details
7/27/2017Bank of America CorporationBoost Price TargetPositive -> Buy$140.00 -> $150.00HighView Rating Details
7/27/2017Jefferies Group LLCBoost Price TargetBuy$115.00 -> $132.00HighView Rating Details
7/17/2017SunTrust Banks, Inc.Boost Price TargetBuy$14.00LowView Rating Details
5/16/2017Goldman Sachs Group, Inc. (The)Initiated CoverageConviction-Buy$138.00LowView Rating Details
3/27/2017Evercore ISIUpgradeIn-Line -> Outperform$98.50 -> $110.00LowView Rating Details
3/20/2017Northland SecuritiesSet Price TargetBuy$105.00LowView Rating Details
2/8/2017Credit Suisse GroupSet Price TargetBuy$120.00N/AView Rating Details
2/5/2017Deutsche Bank AGReiterated RatingHold$100.00N/AView Rating Details
2/2/2017Leerink SwannDowngradeOutperform -> Market PerformN/AView Rating Details
2/2/2017BTIG ResearchDowngradeBuy -> NeutralN/AView Rating Details
1/3/2017GuggenheimUpgradeNeutral -> Buy$120.00N/AView Rating Details
12/10/2016JMP SecuritiesReiterated RatingEqual Weight$130.00N/AView Rating Details
12/1/2016J P Morgan Chase & CoSet Price TargetBuy$120.00N/AView Rating Details
9/11/2016Wells Fargo & CompanyReiterated RatingBuyN/AView Rating Details
8/19/2016Morgan StanleyReiterated RatingBuy$140.00N/AView Rating Details
7/27/2016Citigroup Inc.Boost Price TargetSell$86.00 -> $94.00N/AView Rating Details
6/21/2016Piper Jaffray CompaniesReiterated RatingOverweight$123.00N/AView Rating Details
3/17/2016NomuraInitiated CoverageBuy$101.00N/AView Rating Details
1/4/2016Sterne Agee CRTBoost Price TargetBuy$90.00 -> $92.00N/AView Rating Details
(Data available from 10/20/2015 forward)

Earnings

Earnings History for Edwards Lifesciences Corporation (NYSE:EW)
Earnings by Quarter for Edwards Lifesciences Corporation (NYSE:EW)
Earnings History by Quarter for Edwards Lifesciences Corporation (NYSE EW)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/24/2017$0.83N/AView Earnings Details
7/26/2017Q2 2017$0.88$1.08$839.16 million$842.00 millionViewN/AView Earnings Details
4/25/2017Q1 2017$0.82$0.94$776.51 million$883.50 millionViewN/AView Earnings Details
2/1/2017Q416$0.72$0.75$760.85 million$767.70 millionViewN/AView Earnings Details
10/25/2016Q316$0.68$0.68$749.14 million$739.40 millionViewN/AView Earnings Details
7/26/2016Q216$0.70$0.76$724.26 million$759.30 millionViewN/AView Earnings Details
4/26/2016Q116$0.66$0.71$664.53 million$697.30 millionViewN/AView Earnings Details
2/2/2016Q415$0.62$0.63$647.44 million$671.10 millionViewN/AView Earnings Details
10/26/2015Q315$0.98$1.07$598.29 million$615.00 millionViewN/AView Earnings Details
7/28/2015Q215$1.05$1.13$604.97 million$616.80 millionViewN/AView Earnings Details
4/23/2015Q115$1.04$1.12$585.16 million$590.30 millionViewN/AView Earnings Details
2/3/2015Q414$0.95$1.06$610.50 million$618.00 millionViewListenView Earnings Details
10/23/2014Q314$0.72$0.80$546.10 million$607.40 millionViewListenView Earnings Details
7/29/2014Q214$0.77$0.88$545.10 million$547.00 millionViewListenView Earnings Details
4/24/2014Q114$0.69$0.76$523.10 million$522.40 millionViewListenView Earnings Details
2/3/2014Q413$0.82$0.91$533.82 million$536.00 millionViewN/AView Earnings Details
10/28/2013Q313$0.66$0.68$490.96 million$496.00 millionViewN/AView Earnings Details
7/25/2013Q2 2013$0.76$0.82$514.59 million$517.20 millionViewN/AView Earnings Details
4/23/2013Q1 2013$0.76$0.72$518.69 million$496.70 millionViewN/AView Earnings Details
2/4/2013Q4 2012$0.77$0.77$499.46 million$510.50 millionViewN/AView Earnings Details
10/19/2012$0.56$0.58ViewN/AView Earnings Details
7/24/2012$0.66$0.67ViewN/AView Earnings Details
2/2/2012$0.59$0.62ViewN/AView Earnings Details
10/19/2011$0.39$0.38ViewN/AView Earnings Details
7/21/2011$0.50$0.49ViewN/AView Earnings Details
4/20/2011$0.42$0.51ViewN/AView Earnings Details
2/2/2011$0.53$0.55ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Edwards Lifesciences Corporation (NYSE:EW)
2017 EPS Consensus Estimate: $3.44
2018 EPS Consensus Estimate: $4.05
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174$0.82$0.85$0.84
Q2 20174$0.87$0.89$0.88
Q3 20174$0.79$0.86$0.84
Q4 20174$0.88$0.92$0.89
Q1 20183$0.95$1.10$1.03
Q2 20183$1.04$1.09$1.06
Q3 20183$0.92$0.98$0.95
Q4 20183$0.96$1.05$1.02
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Edwards Lifesciences Corporation (NYSE:EW)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Edwards Lifesciences Corporation (NYSE:EW)
Insider Ownership Percentage: 2.13%
Institutional Ownership Percentage: 81.90%
Insider Trades by Quarter for Edwards Lifesciences Corporation (NYSE:EW)
Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)
Insider Trades by Quarter for Edwards Lifesciences Corporation (NYSE:EW)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/16/2017Larry L WoodVPSell18,960$108.54$2,057,918.40View SEC Filing  
9/29/2017Donald E. Bobo, Jr.VPSell5,300$108.86$576,958.00View SEC Filing  
9/15/2017Larry L. WoodVPSell18,960$112.58$2,134,516.80View SEC Filing  
9/7/2017Michael A. MussallemCEOSell32,900$112.45$3,699,605.00View SEC Filing  
8/30/2017Larry L. WoodVPSell18,960$111.81$2,119,917.60View SEC Filing  
8/29/2017Donald E. Bobo, Jr.VPSell5,300$112.15$594,395.00View SEC Filing  
8/9/2017Michael A. MussallemCEOSell32,900$115.99$3,816,071.00View SEC Filing  
8/4/2017Donald E. Bobo, Jr.VPSell25,000$116.00$2,900,000.00View SEC Filing  
7/31/2017Catherine M. SzymanVPSell4,681$115.78$541,966.18View SEC Filing  
7/31/2017Michael A. MussallemCEOSell32,900$114.80$3,776,920.00View SEC Filing  
7/28/2017Donald E. Bobo, Jr.VPSell5,300$114.68$607,804.00View SEC Filing  
6/29/2017Donald E. Bobo, Jr.VPSell5,600$117.15$656,040.00View SEC Filing  
6/7/2017Michael A. MussallemCEOSell32,900$118.05$3,883,845.00View SEC Filing  
5/31/2017Patrick B. VerguetVPSell10,000$114.88$1,148,800.00View SEC Filing  
5/19/2017Dylan SidooDirectorBuy25,000$0.11$2,750.00
5/19/2017Patrick B. VerguetVPSell22,631$113.16$2,560,923.96View SEC Filing  
5/15/2017Patrick B. VerguetVPSell11,500$111.64$1,283,860.00View SEC Filing  
5/8/2017Donald E. Bobo, Jr.VPSell19,100$110.34$2,107,494.00View SEC Filing  
5/4/2017Donald E. Bobo, Jr.VPSell34,120$109.98$3,752,517.60View SEC Filing  
5/3/2017Michael A. MussallemCEOSell49,100$109.71$5,386,761.00View SEC Filing  
4/28/2017Michael A. MussallemCEOSell49,100$109.78$5,390,198.00View SEC Filing  
4/27/2017Bernard J. ZovighianVPSell18,050$109.21$1,971,240.50View SEC Filing  
4/5/2017Donald E. Bobo, Jr.VPSell13,720$93.58$1,283,917.60View SEC Filing  
3/30/2017Patrick B. VerguetVPSell24,000$93.90$2,253,600.00View SEC Filing  
3/6/2017Donald E. Bobo, Jr.VPSell13,720$90.01$1,234,937.20View SEC Filing  
2/16/2017Michael A. MussallemCEOSell49,100$89.63$4,400,833.00View SEC Filing  
2/3/2017Kieran GallahueDirectorBuy3,000$90.10$270,300.00View SEC Filing  
1/13/2017Michael A. MussallemCEOSell49,100$97.08$4,766,628.00View SEC Filing  
1/12/2017Donald E. Bobo, Jr.VPSell13,720$97.47$1,337,288.40View SEC Filing  
1/12/2017Dylan SidooDirectorBuy30,000$0.13$3,900.00
1/11/2017Dylan SidooDirectorBuy20,000$0.13$2,600.00
12/19/2016Michael A. MussallemCEOSell49,100$91.96$4,515,236.00View SEC Filing  
12/5/2016Huimin WangVPSell13,650$83.53$1,140,184.50View SEC Filing  
12/1/2016Larry L. WoodVPSell13,258$81.85$1,085,167.30View SEC Filing  
11/30/2016Catherine M. SzymanVPBuy12,870$83.43$1,073,744.10View SEC Filing  
11/29/2016Kieran GallahueDirectorBuy3,000$84.63$253,890.00View SEC Filing  
11/22/2016Michael A. MussallemCEOSell49,100$84.67$4,157,297.00View SEC Filing  
11/7/2016Huimin WangVPSell13,650$91.29$1,246,108.50View SEC Filing  
11/2/2016Donald E. Bobo, Jr.VPSell15,000$90.13$1,351,950.00View SEC Filing  
11/1/2016Larry L. WoodVPSell13,257$93.27$1,236,480.39View SEC Filing  
10/27/2016Michael A. MussallemCEOSell49,100$92.77$4,555,007.00View SEC Filing  
10/5/2016Huimin WangVPSell13,650$120.04$1,638,546.00View SEC Filing  
10/3/2016Larry L. WoodVPSell13,257$119.27$1,581,162.39View SEC Filing  
9/6/2016Huimin WangVPSell13,650$115.72$1,579,578.00View SEC Filing  
9/2/2016Donald E. Bobo, Jr.VPSell18,000$115.78$2,084,040.00View SEC Filing  
8/26/2016Patrick B. VerguetVPSell5,000$114.88$574,400.00View SEC Filing  
8/24/2016Patrick B. VerguetVPSell5,000$116.81$584,050.00View SEC Filing  
8/23/2016Patrick B. VerguetVPSell10,092$117.53$1,186,112.76View SEC Filing  
8/11/2016Michael A. MussallemCEOSell49,100$114.01$5,597,891.00View SEC Filing  
8/10/2016John T. CardisDirectorSell5,000$113.21$566,050.00View SEC Filing  
8/9/2016Patrick B. VerguetVPSell10,000$113.48$1,134,800.00View SEC Filing  
8/5/2016Huimin WangVPSell13,650$113.03$1,542,859.50View SEC Filing  
8/1/2016Larry L. WoodVPSell13,257$114.24$1,514,479.68View SEC Filing  
8/1/2016Schack Wesley W. VonDirectorSell6,000$113.98$683,880.00View SEC Filing  
7/29/2016Robert W.A. SellersVPSell10,000$114.33$1,143,300.00View SEC Filing  
7/28/2016Michael A. MussallemCEOSell49,100$113.31$5,563,521.00View SEC Filing  
7/5/2016Huimin WangVPSell13,650$98.44$1,343,706.00View SEC Filing  
7/1/2016Larry L. WoodVPSell13,257$98.79$1,309,659.03View SEC Filing  
6/8/2016Michael A MussallemCEOSell49,100$102.75$5,045,025.00View SEC Filing  
6/6/2016Huimin WangVPSell13,650$101.34$1,383,291.00View SEC Filing  
6/3/2016Larry L WoodVPSell13,257$101.38$1,343,994.66View SEC Filing  
5/31/2016Donald E Bobo JrVPSell18,000$99.04$1,782,720.00View SEC Filing  
5/24/2016Steven R LorangerDirectorBuy5,000$101.07$505,350.00View SEC Filing  
5/18/2016Patrick B VerguetVPSell13,000$102.75$1,335,750.00View SEC Filing  
5/17/2016Patrick B VerguetVPSell5,000$105.00$525,000.00View SEC Filing  
5/16/2016Patrick B VerguetVPSell3,000$104.62$313,860.00View SEC Filing  
5/5/2016Huimin WangVPSell13,650$103.36$1,410,864.00View SEC Filing  
5/5/2016Michael A MussallemCEOSell59,000$104.12$6,143,080.00View SEC Filing  
5/2/2016Patrick B VerguetVPSell7,000$106.86$748,020.00View SEC Filing  
4/29/2016Michael A MussallemCEOSell59,000$106.13$6,261,670.00View SEC Filing  
4/5/2016Huimin WangVPSell13,650$103.97$1,419,190.50View SEC Filing  
3/17/2016Michael A MussallemCEOSell59,000$84.39$4,979,010.00View SEC Filing  
3/7/2016Huimin WangVPSell13,650$87.17$1,189,870.50View SEC Filing  
2/18/2016Michael A. MussallemCEOSell59,000$86.94$5,129,460.00View SEC Filing  
2/18/2016Patrick B. VerguetVPSell5,000$87.00$435,000.00View SEC Filing  
2/16/2016Patrick B. VerguetVPSell8,000$81.58$652,640.00View SEC Filing  
2/5/2016Huimin WangVPSell13,650$83.46$1,139,229.00View SEC Filing  
2/4/2016Barbara J. McneilDirectorSell4,000$83.29$333,160.00View SEC Filing  
1/21/2016Patrick B. VerguetVPSell8,000$77.00$616,000.00View SEC Filing  
1/6/2016Nick DemareDirectorBuy15,000$0.08$1,200.00
1/5/2016Huimin WangVPSell13,650$78.50$1,071,525.00View SEC Filing  
1/5/2016Michael A. MussallemCEOSell59,000$79.82$4,709,380.00View SEC Filing  
12/17/2015Michael A. MussallemCEOSell59,000$81.85$4,829,150.00View SEC Filing  
12/15/2015Patrick B. VerguetVPSell8,000$80.87$646,960.00View SEC Filing  
12/4/2015Huimin WangVPSell6,880$157.96$1,086,764.80View SEC Filing  
11/27/2015Patrick B. VerguetVPSell7,500$164.50$1,233,750.00View SEC Filing  
11/23/2015Robert W.A. SellersVPSell19,200$157.13$3,016,896.00View SEC Filing  
11/17/2015Patrick B. VerguetVPSell4,000$154.50$618,000.00View SEC Filing  
11/5/2015Huimin WangVPSell6,920$156.01$1,079,589.20View SEC Filing  
11/3/2015Patrick B. VerguetVPSell4,338$158.48$687,486.24View SEC Filing  
10/30/2015Patrick B. VerguetVPSell22,000$155.09$3,411,980.00View SEC Filing  
10/29/2015Michael A MussallemCEOSell29,500$154.59$4,560,405.00View SEC Filing  
10/5/2015Huimin WangVPSell6,920$154.30$1,067,756.00View SEC Filing  
10/2/2015Patrick B. VerguetVPSell4,000$154.00$616,000.00View SEC Filing  
10/1/2015Larry L. WoodVPSell7,680$141.52$1,086,873.60View SEC Filing  
9/21/2015Michael A. MussallemCEOSell29,500$142.49$4,203,455.00View SEC Filing  
9/4/2015Huimin WangVPSell6,920$135.19$935,514.80View SEC Filing  
9/1/2015Larry L. WoodVPSell7,680$137.50$1,056,000.00View SEC Filing  
8/24/2015Michael A. MussallemCEOSell29,500$135.25$3,989,875.00View SEC Filing  
8/13/2015West Petroleum Corp. EastInsiderBuy25,000$0.12$2,875.00
7/6/2015Huimin WangVPSell6,920$143.95$996,134.00View SEC Filing  
7/1/2015Larry L WoodVPSell7,680$143.51$1,102,156.80View SEC Filing  
6/24/2015Michael A MussallemCEOSell29,500$143.71$4,239,445.00View SEC Filing  
6/5/2015Huimin WangVPSell6,920$131.39$909,218.80View SEC Filing  
6/1/2015Larry L WoodVPSell7,680$130.47$1,002,009.60View SEC Filing  
5/29/2015Patrick B VerguetVPSell9,662$131.18$1,267,461.16View SEC Filing  
5/21/2015Barbara J McneilDirectorSell2,000$132.59$265,180.00View SEC Filing  
5/19/2015Robert Marc BustinDirectorSell10,000$0.18$1,750.00
5/1/2015Larry L WoodVPSell7,680$127.12$976,281.60View SEC Filing  
4/30/2015Michael A MussallemCEOSell29,500$128.99$3,805,205.00View SEC Filing  
4/6/2015Huimin WangVPSell6,920$140.24$970,460.80View SEC Filing  
4/1/2015Larry L WoodVPSell7,680$142.06$1,091,020.80View SEC Filing  
3/31/2015Robert Marc BustinDirectorBuy15,000$0.15$2,250.00
3/26/2015Michael A MussallemCEOSell29,500$140.10$4,132,950.00View SEC Filing  
3/2/2015Larry L WoodVPSell7,680$132.62$1,018,521.60View SEC Filing  
2/6/2015Huimin WangVPSell6,920$134.79$932,746.80View SEC Filing  
1/5/2015Huimin WangVPSell6,920$126.60$876,072.00View SEC Filing  
1/5/2015Michael A MussallemCEOSell29,500$128.20$3,781,900.00View SEC Filing  
12/22/2014Michael A MussallemCEOSell29,500$133.01$3,923,795.00View SEC Filing  
11/24/2014Michael A MussallemCEOSell29,500$124.25$3,665,375.00View SEC Filing  
11/13/2014Robert W.A. SellersVPSell3,400$124.27$422,518.00View SEC Filing  
11/10/2014Patrick B VerguetVPSell5,000$123.70$618,500.00View SEC Filing  
11/7/2014Schack Wesley W VonDirectorSell3,655$123.00$449,565.00View SEC Filing  
11/5/2014Huimin WangVPSell5,600$120.26$673,456.00View SEC Filing  
10/28/2014Barbara J McneilDirectorSell1,000$117.94$117,940.00View SEC Filing  
10/28/2014Michael A MussallemCEOSell29,500$117.06$3,453,270.00View SEC Filing  
10/28/2014Patrick B VerguetVPSell15,000$117.33$1,759,950.00View SEC Filing  
10/28/2014West Petroleum Corp. EastInsiderBuy15,000$0.12$1,800.00
10/27/2014Patrick B VerguetVPSell10,000$117.00$1,170,000.00View SEC Filing  
10/27/2014West Petroleum Corp. EastInsiderBuy20,000$0.13$2,600.00
10/24/2014Donald E Bobo JrVPSell30,000$114.25$3,427,500.00View SEC Filing  
10/24/2014West Petroleum Corp. EastInsiderBuy35,000$0.14$4,725.00
10/23/2014West Petroleum Corp. EastInsiderBuy40,000$0.15$5,800.00
10/6/2014Huimin WangVPSell5,600$107.00$599,200.00View SEC Filing  
10/3/2014Donald E Bobo JrVPSell25,000$105.00$2,625,000.00View SEC Filing  
9/29/2014Michael A MussallemCEOSell29,500$102.71$3,029,945.00View SEC Filing  
9/10/2014Donald E Bobo JrVPSell25,000$100.00$2,500,000.00View SEC Filing  
9/5/2014Huimin WangVPSell5,600$98.29$550,424.00View SEC Filing  
8/27/2014Carlyn D SolomonVPSell85,200$97.85$8,336,820.00View SEC Filing  
8/27/2014Michael A MussallemCEOSell29,500$98.14$2,895,130.00View SEC Filing  
8/18/2014John T CardisDirectorSell6,000$97.92$587,520.00View SEC Filing  
8/18/2014Larry L WoodVPSell63,752$97.85$6,238,133.20View SEC Filing  
8/13/2014Patrick B VerguetVPSell7,800$95.50$744,900.00View SEC Filing  
8/5/2014Patrick B VerguetVPSell15,000$94.05$1,410,750.00View SEC Filing  
8/4/2014Patrick B VerguetVPSell5,000$93.00$465,000.00View SEC Filing  
8/1/2014Patrick B VerguetVPSell5,000$92.00$460,000.00View SEC Filing  
7/31/2014Michael A MussallemCEOSell29,500$91.98$2,713,410.00View SEC Filing  
7/31/2014Robert Alexander IngramDirectorSell12,500$90.26$1,128,250.00View SEC Filing  
7/31/2014Robert W.A. SellersVPSell8,850$91.47$809,509.50View SEC Filing  
7/30/2014Donald E Bobo JrVPSell23,270$92.00$2,140,840.00View SEC Filing  
7/7/2014Huimin WangVPSell5,600$87.79$491,624.00View SEC Filing  
6/27/2014Donald E Bobo JrVPSell25,000$87.00$2,175,000.00View SEC Filing  
6/24/2014Michael A MussallemCEOSell29,500$85.38$2,518,710.00View SEC Filing  
6/5/2014Huimin WangVPSell5,600$80.73$452,088.00View SEC Filing  
5/30/2014Barbara J McneilDirectorSell1,200$81.20$97,440.00View SEC Filing  
5/28/2014Michael A MussallemCEOSell29,500$79.33$2,340,235.00View SEC Filing  
4/14/2014Donald Bobo, Jr.VPSell25,000$82.00$2,050,000.00View SEC Filing  
4/10/2014Michael MussallemCEOSell29,500$74.71$2,203,945.00View SEC Filing  
4/7/2014Huimin WangVPSell5,600$74.03$414,568.00View SEC Filing  
3/24/2014Michael BowlinDirectorSell1,093$72.33$79,056.69View SEC Filing  
3/6/2014Robert W.A. SellersVPSell1,650$72.88$120,252.00View SEC Filing  
2/6/2014Michael MussallemCEOSell29,500$66.92$1,974,140.00View SEC Filing  
1/27/2014Michael BowlinDirectorSell1,092$68.65$74,965.80View SEC Filing  
1/9/2014Michael MussallemCEOSell29,500$67.04$1,977,680.00View SEC Filing  
1/6/2014Huimin WangVPSell5,600$67.14$375,984.00View SEC Filing  
12/11/2013Patrick VerguetVPSell10,000$62.34$623,400.00View SEC Filing  
12/5/2013Huimin WangVPSell4,650$64.65$300,622.50View SEC Filing  
12/4/2013Michael MussallemCEOSell29,500$64.90$1,914,550.00View SEC Filing  
10/9/2013Michael MussallemCEOSell29,500$72.63$2,142,585.00View SEC Filing  
10/4/2013Huimin WangVPSell4,850$72.19$350,121.50View SEC Filing  
9/12/2013Michael MussallemCEOSell29,500$71.82$2,118,690.00View SEC Filing  
9/5/2013Huimin WangVPSell4,850$71.24$345,514.00View SEC Filing  
8/8/2013Michael MussallemCEOSell29,500$72.28$2,132,260.00View SEC Filing  
8/5/2013Huimin WangVPSell4,850$72.30$350,655.00View SEC Filing  
8/1/2013Patrick VerguetVPSell20,000$73.15$1,463,000.00View SEC Filing  
7/10/2013Michael A MussallemCEOSell29,500$65.60$1,935,200.00View SEC Filing  
7/5/2013Huimin WangVPSell4,850$65.69$318,596.50View SEC Filing  
6/6/2013Michael A MussallemCEOSell29,500$66.25$1,954,375.00View SEC Filing  
6/5/2013Huimin WangVPSell4,850$65.11$315,783.50View SEC Filing  
5/13/2013Paul C RedmondVPSell5,000$67.35$336,750.00View SEC Filing  
5/8/2013Michael A MussallemCEOSell29,200$64.24$1,875,808.00View SEC Filing  
5/7/2013Thomas M AbateCFOSell15,000$63.75$956,250.00View SEC Filing  
5/3/2013Schack Wesley W VonDirectorBuy1,000$64.00$64,000.00View SEC Filing  
5/1/2013David E I PyottDirectorBuy3,000$62.95$188,850.00View SEC Filing  
5/1/2013John H Kehl JrVPSell12,500$62.72$784,000.00View SEC Filing  
4/26/2013Schack Wesley W VonDirectorBuy2,000$64.95$129,900.00View SEC Filing  
4/10/2013Michael A MussallemCEOSell35,000$83.37$2,917,950.00View SEC Filing  
3/13/2013John H Kehl JrVPSell12,500$87.75$1,096,875.00View SEC Filing  
10/5/2012Huimin WangVPSell6,250$109.88$686,750.00View SEC Filing  
10/4/2012Donald E Bobo JrVPSell11,530$110.14$1,269,914.20View SEC Filing  
8/9/2012Michael A MussallemCEOSell35,000$98.69$3,454,150.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Edwards Lifesciences Corporation (NYSE:EW)
Latest Headlines for Edwards Lifesciences Corporation (NYSE:EW)
Source:
DateHeadline
nasdaq.com logoWill Edwards Lifesciences (EW) Gain on THVT in Q3 Earnings? - Nasdaq
www.nasdaq.com - October 19 at 5:58 AM
finance.yahoo.com logoWill Edwards Lifesciences (EW) Gain on THVT in Q3 Earnings?
finance.yahoo.com - October 18 at 7:51 PM
finance.yahoo.com logoNike among today's IQ100 leaders
finance.yahoo.com - October 17 at 7:10 PM
americanbankingnews.com logoZacks: Analysts Anticipate Edwards Lifesciences Corporation (EW) Will Announce Quarterly Sales of $833.89 Million
www.americanbankingnews.com - October 17 at 4:50 AM
americanbankingnews.com logoEdwards Lifesciences Corporation (EW) to Release Earnings on Tuesday
www.americanbankingnews.com - October 17 at 3:22 AM
americanbankingnews.com logoEdwards Lifesciences Corporation (EW) VP Larry L. Wood Sells 18,960 Shares
www.americanbankingnews.com - October 16 at 7:22 PM
nasdaq.com logoEdwards Lifesciences Takes Over #65 Spot From Mid-America Apartment Communities
www.nasdaq.com - October 16 at 6:56 PM
finance.yahoo.com logoAnalysts’ Recommendations for Edwards Lifesciences before 3Q17
finance.yahoo.com - October 16 at 6:56 PM
finance.yahoo.com logoEdwards Lifesciences Stock Gaining Momentum: What’s Next?
finance.yahoo.com - October 16 at 6:56 PM
americanbankingnews.com logoEdwards Lifesciences Corporation (EW) Earns "Buy" Rating from Cowen and Company
www.americanbankingnews.com - October 14 at 11:26 PM
finance.yahoo.com logoWhat to Expect from Edwards Lifesciences’ Fiscal 3Q17 Results
finance.yahoo.com - October 13 at 4:02 PM
finance.yahoo.com logoEdwards Lifesciences: Analysts Expect 12.5% 3Q17 Revenue Growth
finance.yahoo.com - October 13 at 4:02 PM
americanbankingnews.com logoEdwards Lifesciences Corporation (EW) & ViewRay (VRAY) Head-To-Head Survey
www.americanbankingnews.com - October 13 at 8:26 AM
americanbankingnews.com logoLeerink Swann Analysts Lower Earnings Estimates for Edwards Lifesciences Corporation (EW)
www.americanbankingnews.com - October 13 at 8:00 AM
americanbankingnews.com logoFY2019 Earnings Estimate for Edwards Lifesciences Corporation Issued By Leerink Swann (EW)
www.americanbankingnews.com - October 12 at 3:50 PM
prnewswire.com logoEdwards Lifesciences To Host Earnings Conference Call On October 24, 2017 - PR Newswire (press release)
www.prnewswire.com - October 12 at 1:06 AM
finance.yahoo.com logoEdwards Lifesciences To Host Earnings Conference Call On October 24, 2017
finance.yahoo.com - October 11 at 8:01 PM
bizjournals.com logoBreakfast Technical Briefing on Medical Equipment Stocks -- Abbott Laboratories, Boston Scientific, Edwards Lifesciences, and Medtronic
www.bizjournals.com - October 10 at 4:13 PM
americanbankingnews.com logoEdwards Lifesciences Corporation (EW) Receives "Buy" Rating from Canaccord Genuity
www.americanbankingnews.com - October 9 at 2:34 PM
finance.yahoo.com logo3 Top Med-Tech Stocks You Can Buy Right Now
finance.yahoo.com - October 8 at 5:21 PM
americanbankingnews.com logoEdwards Lifesciences Corporation (EW) & Its Competitors Critical Survey
www.americanbankingnews.com - October 7 at 8:24 PM
americanbankingnews.com logoNatus Medical (BABY) vs. Edwards Lifesciences Corporation (EW) Financial Contrast
www.americanbankingnews.com - October 7 at 6:52 AM
finance.yahoo.com logoCramer's lightning round: Promotional activity works for ...
finance.yahoo.com - October 4 at 5:03 AM
americanbankingnews.com logoEdwards Lifesciences Corporation (EW) Short Interest Update
www.americanbankingnews.com - October 3 at 2:18 AM
americanbankingnews.com logoEdwards Lifesciences Corporation (EW) VP Donald E. Bobo, Jr. Sells 5,300 Shares
www.americanbankingnews.com - October 2 at 10:28 PM
americanbankingnews.com logoEdwards Lifesciences Corporation's (EW) Equal Weight Rating Reiterated at Barclays PLC
www.americanbankingnews.com - September 30 at 10:28 AM
americanbankingnews.com logoBoston Scientific Corporation (BSX) vs. Edwards Lifesciences Corporation (EW) Head-To-Head Survey
www.americanbankingnews.com - September 30 at 12:30 AM
americanbankingnews.com logoReviewing Edwards Lifesciences Corporation (EW) and Its Peers
www.americanbankingnews.com - September 29 at 4:32 PM
zacks.com logoMedtronic (MDT) Initiates Study on CoreValve Evolut PRO TAVI
www.zacks.com - September 28 at 1:14 PM
americanbankingnews.com logo Brokerages Anticipate Edwards Lifesciences Corporation (EW) Will Announce Quarterly Sales of $834.36 Million
www.americanbankingnews.com - September 28 at 3:56 AM
americanbankingnews.com logoEdwards Lifesciences Corporation (EW) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - September 27 at 8:42 PM
americanbankingnews.com logo Brokerages Anticipate Edwards Lifesciences Corporation (EW) to Announce $0.87 Earnings Per Share
www.americanbankingnews.com - September 26 at 10:08 PM
americanbankingnews.com logoReviewing Edwards Lifesciences Corp (EW) and Its Rivals
www.americanbankingnews.com - September 24 at 6:18 PM
finance.yahoo.com logoEdwards Announces Key Events For PCR London Valves 2017
finance.yahoo.com - September 24 at 4:10 AM
americanbankingnews.com logoIntuitive Surgical (ISRG) versus Edwards Lifesciences Corporation (EW) Head to Head Comparison
www.americanbankingnews.com - September 23 at 6:14 PM
nasdaq.com logoMedtronic Advances in Pain Therapy With US Intellis Launch - Nasdaq
www.nasdaq.com - September 22 at 10:37 PM
nasdaq.com logoWhy is Edwards Lifesciences (EW) a Strong Buy Stock Now? - Nasdaq
www.nasdaq.com - September 22 at 8:20 AM
finance.yahoo.com logoWhy is Edwards Lifesciences (EW) a Strong Buy Stock Now?
finance.yahoo.com - September 21 at 6:38 PM
nasdaq.com logoHalyard Health (HYH) Announces Positive Data on COOLIEF - Nasdaq
www.nasdaq.com - September 20 at 7:26 PM
nasdaq.com logoBoston Scientific MultiSENSE Study on HeartLogic Positive - Nasdaq
www.nasdaq.com - September 20 at 7:26 PM
nasdaq.com logoBecton, Dickinson Ultra-Fine Needle to Improve Diabetic Care - Nasdaq
www.nasdaq.com - September 20 at 7:26 PM
nasdaq.com logoNeogen (NEOG) Earnings and Revenues Beat Estimates in Q1 - Nasdaq
www.nasdaq.com - September 20 at 7:26 PM
finance.yahoo.com logoMasimo (MASI) Launches Rad-97 CO-Oximeter Post FDA Clearance
finance.yahoo.com - September 19 at 6:28 PM
finance.yahoo.com logoSurmodics Receives FDA's Approval for PTA Balloon Catheter
finance.yahoo.com - September 19 at 6:28 PM
americanbankingnews.com logoEdwards Lifesciences Corporation (EW) versus Its Competitors Head-To-Head Contrast
www.americanbankingnews.com - September 19 at 10:51 AM
americanbankingnews.com logoInsider Selling: Edwards Lifesciences Corporation (EW) VP Sells 18,960 Shares of Stock
www.americanbankingnews.com - September 18 at 7:22 PM
finance.yahoo.com logoMcKesson to Gain From Distribution Business Amid Pricing Woes
finance.yahoo.com - September 18 at 6:17 PM
nasdaq.com logoSurmodics Presents Encouraging SurVeil DCB Data at VIVA Meet ... - Nasdaq
www.nasdaq.com - September 15 at 7:03 PM
nasdaq.com logoThermo Fisher Fundamentals Impressive Amid Tough Competition - Nasdaq
www.nasdaq.com - September 15 at 7:03 PM
finance.yahoo.com logoAllscripts' Latest Initiative Eradicates Price Ambiguity
finance.yahoo.com - September 15 at 7:03 PM

Social

Chart

Edwards Lifesciences Corporation (EW) Chart for Friday, October, 20, 2017

This page was last updated on 10/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.